株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

野兎病:パイプライン製品の分析

Tularaemia - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 293888
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.38円で換算しております。
Back to Top
野兎病:パイプライン製品の分析 Tularaemia - Pipeline Review, H2 2017
出版日: 2017年11月14日 ページ情報: 英文 72 Pages
概要

野兎病(ツラレミア)は、野兎病菌(Francisella tularensis)と呼ばれる細菌に起因する感染症です。主に節足動物(特にダニや蚊)に咬まれることで感染します。皮膚、結膜嚢、口腔咽頭粘膜を介して、感染した動物や動物性物質との直接接触、汚染された食品や水の摂取、汚染されたほこりやエアロゾルの吸入によって感染します。症状は、皮膚潰瘍、リンパ腺の腫れや痛み、発熱、悪寒などです。治療には、抗生物質や健康的な生活スタイルが推奨されています。

当レポートでは、野兎病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

野兎病の概要

治療薬の開発

  • パイプライン製品:概要
  • 企業別のパイプライン
  • 大学/研究機関で開発されたパイプライン
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • Aradigm Corp
  • Arno Therapeutics Inc
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Grifols SA
  • Merck & Co Inc
  • Tetraphase Pharmaceuticals Inc

薬剤のプロファイル

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9886IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Tularaemia - Overview 6
  • Tularaemia - Therapeutics Development 7
  • Pipeline Overview 7
  • Pipeline by Companies 8
  • Pipeline by Universities/Institutes 9
  • Products under Development by Companies 10
  • Products under Development by Universities/Institutes 11
  • Tularaemia - Therapeutics Assessment 12
  • Assessment by Target 12
  • Assessment by Mechanism of Action 14
  • Assessment by Route of Administration 16
  • Assessment by Molecule Type 18
  • Tularaemia - Companies Involved in Therapeutics Development 20
  • Aradigm Corp 20
  • Arno Therapeutics Inc 20
  • DynPort Vaccine Company LLC 21
  • Emergent BioSolutions Inc 21
  • EpiVax Inc 22
  • Grifols SA 22
  • Merck & Co Inc 22
  • Tetraphase Pharmaceuticals Inc 23
  • Tularaemia - Drug Profiles 24
  • AR-12 - Drug Profile 24
  • Product Description 24
  • Mechanism Of Action 24
  • R&D Progress 24
  • ARD-3100 - Drug Profile 27
  • Product Description 27
  • Mechanism Of Action 27
  • R&D Progress 27
  • ARD-3150 - Drug Profile 31
  • Product Description 31
  • Mechanism Of Action 31
  • R&D Progress 31
  • ciprofloxacin hydrochloride - Drug Profile 38
  • Product Description 38
  • Mechanism Of Action 38
  • R&D Progress 38
  • EV-035 - Drug Profile 39
  • Product Description 39
  • Mechanism Of Action 39
  • R&D Progress 39
  • infectious disease vaccines - Drug Profile 41
  • Product Description 41
  • Mechanism Of Action 41
  • R&D Progress 41
  • NDBR-101 - Drug Profile 42
  • Product Description 42
  • Mechanism Of Action 42
  • R&D Progress 42
  • Small Molecules for Infectious Diseases - Drug Profile 43
  • Product Description 43
  • Mechanism Of Action 43
  • R&D Progress 43
  • solithromycin - Drug Profile 44
  • Product Description 44
  • Mechanism Of Action 44
  • R&D Progress 44
  • SRI-011225 - Drug Profile 58
  • Product Description 58
  • Mechanism Of Action 58
  • R&D Progress 58
  • TP-271 - Drug Profile 59
  • Product Description 59
  • Mechanism Of Action 59
  • R&D Progress 59
  • tularaemia [strain A] vaccine - Drug Profile 62
  • Product Description 62
  • Mechanism Of Action 62
  • R&D Progress 62
  • tularaemia [strain B] vaccine - Drug Profile 63
  • Product Description 63
  • Mechanism Of Action 63
  • R&D Progress 63
  • tularaemia vaccine - Drug Profile 64
  • Product Description 64
  • Mechanism Of Action 64
  • R&D Progress 64
  • tularemia vaccine - Drug Profile 65
  • Product Description 65
  • Mechanism Of Action 65
  • R&D Progress 65
  • Tularaemia - Dormant Projects 66
  • Tularaemia - Discontinued Products 67
  • Tularaemia - Product Development Milestones 68
  • Featured News & Press Releases 68
  • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 68
  • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 69
  • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 69
  • Appendix 71
  • Methodology 71
  • Coverage 71
  • Secondary Research 71
  • Primary Research 71
  • Expert Panel Validation 71
  • Contact Us 71
  • Disclaimer 72

List of Tables

  • Number of Products under Development for Tularaemia, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Products under Development by Companies, H2 2017 10
  • Products under Development by Universities/Institutes, H2 2017 11
  • Number of Products by Stage and Target, H2 2017 13
  • Number of Products by Stage and Mechanism of Action, H2 2017 15
  • Number of Products by Stage and Route of Administration, H2 2017 17
  • Number of Products by Stage and Molecule Type, H2 2017 19
  • Tularaemia - Pipeline by Aradigm Corp, H2 2017 20
  • Tularaemia - Pipeline by Arno Therapeutics Inc, H2 2017 20
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2017 21
  • Tularaemia - Pipeline by Emergent BioSolutions Inc, H2 2017 21
  • Tularaemia - Pipeline by EpiVax Inc, H2 2017 22
  • Tularaemia - Pipeline by Grifols SA, H2 2017 22
  • Tularaemia - Pipeline by Merck & Co Inc, H2 2017 23
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 23
  • Tularaemia - Dormant Projects, H2 2017 66
  • Tularaemia - Discontinued Products, H2 2017 67

List of Figures

  • Number of Products under Development for Tularaemia, H2 2017 7
  • Number of Products under Development by Companies, H2 2017 8
  • Number of Products under Development by Universities/Institutes, H2 2017 9
  • Number of Products by Top 10 Targets, H2 2017 12
  • Number of Products by Stage and Top 10 Targets, H2 2017 12
  • Number of Products by Top 10 Mechanism of Actions, H2 2017 14
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14
  • Number of Products by Routes of Administration, H2 2017 16
  • Number of Products by Stage and Routes of Administration, H2 2017 16
  • Number of Products by Molecule Types, H2 2017 18
  • Number of Products by Stage and Molecule Types, H2 2017 18
Back to Top